Effectiveness of Step-Wise Intervention Plan for Managing Nelfinavir-Associated Diarrhea: A Pilot Study

REFERENCES

• Viracept (nelfinavir mesylate), Product Monograph. Pfizer Canada Inc. Revised September 16, 2004.
   Google Scholar
• Andrade A, Sears C, Rufo P, Lencer W, Flexner C. Charac-terization of nelfinavir (NFV)-associated diarrhea: secretory versus osmotic. In: Program and abstracts of the Confer-ence on Retroviruses and Opportunistic Infections; Janu-ary 30-February 2, 2000; San Francisco, California. 7:87. Abstract 62.
   Google Scholar
• Kertelija M, Sande MA. Diarrhea and AIDS in the era of highly active antiretroviral therapy. Clin Infect Dis. 2000 ;28(4):701–705.
   Web of Science ®Google Scholar
• Sherman DS, Fish DN. Management of protease inhibitor-associated diarrhea. Clin Infect Dis. 2000;30(6):908–914.
   PubMed Web of Science ®Google Scholar
• Hawkins T. Nelfinavir-associated diarrhea is manageable with non-prescription medications. In: Program and ab-stracts of the 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 12401
   Google Scholar
• Perez-Rodriguez E, Gonzalez L, Kopp B. The role of cal-cium supplements in the treatment of Nelfinavir-induced diarrhea. In: Program and abstracts of the 9th Interscience Conference on Antimicrobial Agents and Chemotherapy. September 26–29, 1999; San Francisco, California. Ab-stract 1308.
   Google Scholar
• Razzeca K, Frye J, Odenheimerz S, et al. The treatment of nelfinavir-induced diarrhea. In: Program and abstracts of the 12th World AIDS Conference; June 28-July 3, 1998; Geneva, Switzerland. Abstract 12383.
   Google Scholar
• Hoffman M. Oat bran tablets are an effective natural supplement for the management of protease inhibitor-in-duced diarrhea. In: Abstracts of the 2nd International Con-ference on Discovery and Clinical Development of Antiretroviral Therapy; December 13–17, 1998; St. Tho-mas, West Indies. Abstract LB7.
   Google Scholar
• Mertz HR, Beck CK, Dixon W, Esquivel MA, Hays RD, Shapiro MF. Validation of a new measure of diarrhea. Dig Dis ScL 1995;40(9):1873–1882.
   PubMed Web of Science ®Google Scholar
• Thielman NM, Rust PF, Guerrant RL. Criterion-related va-lidity of a diarrhea questionnaire in HIV-infected adults. Dig Dis ScL 2002;47(7):1421–1426.
   PubMed Web of Science ®Google Scholar
• Drossman DA, Patrick DL, Whitehead WE, et al. Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J GastroenteroL 2000;95(4):999–1007.
   PubMed Web of Science ®Google Scholar
• Patrick DL, Drossman DA, Frederick 10, DiCesare J, Puder KL. Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis ScL 1998; 43(2):400–411.
   PubMed Web of Science ®Google Scholar
• Holmes WC, Shea JA. A new HIV/AIDS-Targeted Quality of Life (HAT-QoL) instrument: development, reliability, and validity. Med Care. 1998;36(2):138–154.
   PubMed Web of Science ®Google Scholar
• Holmes WC, Shea JA. Performance of a new, HIV/AIDS-Targeted Quality of Life (HAT-QoL) instrument in asymp-tomatic seropositive individuals. Qua/ Life Res. 1997;6(6): 561–571.
   PubMed Web of Science ®Google Scholar
• Ware JE, Snow KK, Kosinski M, Gandek B. SF-36 Health Survey: Manual and Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center; 1993.
   Google Scholar
• Cohen J. Statistical Power Analysis for the Behavioral Sci-ences. 2nd ed. Hillsdale, NJ: Lawrence Erlbaum Associa-tion; 1988.
   Google Scholar
• Kazis LE, Anderson JJ, Meenen RF. Effect sizes for inter-preting change in health status. Med Care. 1989;27:S178–189.
   PubMed Web of Science ®Google Scholar
• Samsa G, Edelman D, Rothman ML, Williams GR, Lipscomb J, Matchar D. Determining clinically important differences in health status measures: a general approach with illustration to the health utilities index mark II. Pharma-coeconomics. 1999;15(2):141–155.
   PubMed Web of Science ®Google Scholar
• Ammassari A, Murri R, Pezzotti P, et al. Self-reported symptoms and medication side effects influence adher-ence to highly active antiretroviral therapy in persons with HIV infection. J Acquir lmmun. 2001;28(5):445–449.
   PubMed Web of Science ®Google Scholar
• Molassiotis A, Nahas-Lopez V, Chung WY, Lam SW, Li CK, Lau TF. Factors associated with adherence to antiretroviral medication in HIV-infected patients. Int J STD AIDS. 2002; 13(5):301–310.
   PubMed Web of Science ®Google Scholar
• Spire B, Duran S, Souville M, Leport C, Raffi F, Moatti JP, APROCO cohort study group. Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Soc Sci Med. 2002;54(10):1481–1496.
   PubMed Web of Science ®Google Scholar
• Lubeck DP, Bennett CL, Mazonson PD, Fifer SK, Fries JF. Quality of life and health service use among HIV-infected patients with chronic diarrhea. J Acquir Immune Defic Syndr. 1993; 6(5):478–484.
   PubMed Web of Science ®Google Scholar
• Badia X, Podzamczer D, Garcia M, Lopez-Lavid C C, Consiglio E. A randomized study comparing instruments for measuring health-related quality of life in HIV-infected patients. Spanish MOS-HIV and MQ0L-HIV Validation Group. Medical Outcomes Study HIV Health Survey. AIDS. 1999;13(13):1727–1735.
   Google Scholar
• Burgoyne RW, Saunders DS. Quality of life among urban Canadian HIV/AIDS clinic outpatients. Int J STD AIDS. 2001 12(8):505–512.
   PubMed Web of Science ®Google Scholar
• Burgoyne R, Renwick, R. Social support and quality of life over time among adults living with HIV in the HAART era. Soc Sc/Med. 2004;58(7):1353–1366.
   PubMed Web of Science ®Google Scholar
• Carrieri P, Spire B, Duran S, et al. Health-related quality of life after 1 year of highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2003;32(1):38–47.
   PubMed Web of Science ®Google Scholar
• Cunningham WE, Shapiro MF, Hays RD, et al. Constitu-tional symptoms and health-related quality of life in pa-tients with symptomatic HIV disease. Am J Med. 1998; 104(2):129–136.
   PubMed Web of Science ®Google Scholar
• Justice AC, Rabeneck L, Hays RD, Wu AW, Bozzette SA. Sensitivity, specificity, reliability, and clinical validity of pro-vider-reported symptoms: a comparison with self-reported symptoms. Outcomes Committee of the AIDS Clinical Trials Group. J Acquir Immune Defic Syndr. 1999;21(2):126–133.
   PubMed Web of Science ®Google Scholar
• Murri R, Ammassari A, Fantoni M, et al. Disease-related factors associated with health-related quality of life in people with nonadvanced HIV disease assessed using an Italian version of the MOS-HIV health survey. J Acquir Immune Defic Syndr Hum Retroyirol. 1997; 16(5):350–356 .
   PubMedGoogle Scholar
• Saunders DS, Burgoyne RW. Evaluating health-related wellbeing outcomes among outpatients adults with human immunodeficiency virus infection in the HAART era. Int J STD AIDS. 2002 ;13(1):683–690.
   PubMed Web of Science ®Google Scholar
• Watson A, Samore MH, Wanke CA. Diarrhea and quality of life in ambulatory HIV-infected patients. Dig Dis Sci. 1996;41(9):1794–1800.
   PubMed Web of Science ®Google Scholar
• Wachtel T, Piette J, Mor V, Stein M, Fleishman J, Carpenter C. Quality of life in persons with human immunodeficiency virus infection: measurement by the medical outcomes study instrument. Ann Intern Med. 1992;116(2):129–137.
   PubMed Web of Science ®Google Scholar
• Snijders F, de Boer JB, Steenbergen B, Schouten M, Danner SA, van Dam FS. Impact of diarrhoea and faecal incontinence on the daily life of HIV-infected patients. AIDS Care. 1998;10(5):629–637.
   PubMed Web of Science ®Google Scholar
• Burgoyne RW, Rourke SB, Behrens DM, et al. Long-term quality of life outcomes among adults living with HIV in the HAART era: the interplay of changes in clinical factors and symptom profile. AIDS Behalf. 2004;8(2):151–163.
   PubMed Web of Science ®Google Scholar